DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,008 filers reported holding DANAHER CORPORATION in Q1 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,119,675 | +3.1% | 4,513 | -0.3% | 1.00% | +15.4% |
Q2 2023 | $1,086,000 | -4.8% | 4,525 | 0.0% | 0.86% | -5.1% |
Q1 2023 | $1,140,481 | -5.0% | 4,525 | 0.0% | 0.91% | -5.9% |
Q4 2022 | $1,201,026 | +0.8% | 4,525 | -1.9% | 0.96% | -3.9% |
Q3 2022 | $1,191,000 | +1.9% | 4,612 | 0.0% | 1.00% | +3.3% |
Q2 2022 | $1,169,000 | -13.9% | 4,612 | -0.4% | 0.97% | +1.8% |
Q1 2022 | $1,357,000 | -11.4% | 4,629 | -0.5% | 0.96% | +0.1% |
Q4 2021 | $1,531,000 | +154.7% | 4,654 | +135.6% | 0.95% | +149.1% |
Q3 2021 | $601,000 | +13.4% | 1,975 | +0.1% | 0.38% | +10.4% |
Q2 2021 | $530,000 | +19.4% | 1,974 | 0.0% | 0.35% | +14.1% |
Q1 2021 | $444,000 | +1.1% | 1,974 | 0.0% | 0.30% | -2.3% |
Q4 2020 | $439,000 | +0.5% | 1,974 | -2.8% | 0.31% | -4.6% |
Q3 2020 | $437,000 | +14.1% | 2,030 | -6.3% | 0.33% | +10.1% |
Q2 2020 | $383,000 | +17.5% | 2,167 | -8.1% | 0.30% | +4.2% |
Q1 2020 | $326,000 | -11.4% | 2,357 | -1.8% | 0.28% | +16.4% |
Q4 2019 | $368,000 | +5.1% | 2,400 | -0.8% | 0.24% | -4.7% |
Q3 2019 | $350,000 | -0.3% | 2,420 | -1.5% | 0.26% | -5.9% |
Q2 2019 | $351,000 | +8.0% | 2,458 | 0.0% | 0.27% | +7.9% |
Q1 2019 | $325,000 | +17.3% | 2,458 | -8.6% | 0.25% | +8.6% |
Q4 2018 | $277,000 | -39.0% | 2,690 | -35.6% | 0.23% | -29.7% |
Q3 2018 | $454,000 | +8.9% | 4,180 | -1.2% | 0.33% | +1.9% |
Q2 2018 | $417,000 | -2.8% | 4,230 | -3.5% | 0.32% | -6.4% |
Q1 2018 | $429,000 | +3.9% | 4,385 | -1.5% | 0.35% | -21.4% |
Q4 2017 | $413,000 | +0.7% | 4,450 | -6.9% | 0.44% | -21.0% |
Q3 2017 | $410,000 | -0.2% | 4,780 | -1.8% | 0.56% | +2.6% |
Q2 2017 | $411,000 | -14.9% | 4,870 | -13.7% | 0.54% | -19.7% |
Q1 2017 | $483,000 | +7.6% | 5,645 | -2.2% | 0.68% | +5.5% |
Q4 2016 | $449,000 | -0.7% | 5,770 | 0.0% | 0.64% | -3.0% |
Q3 2016 | $452,000 | -31.0% | 5,770 | -11.0% | 0.66% | -26.3% |
Q2 2016 | $655,000 | +6.5% | 6,485 | 0.0% | 0.90% | +7.2% |
Q1 2016 | $615,000 | -1.9% | 6,485 | -4.0% | 0.84% | +54.1% |
Q4 2015 | $627,000 | +7.5% | 6,754 | -1.2% | 0.54% | +18.3% |
Q3 2015 | $583,000 | -9.5% | 6,839 | -9.2% | 0.46% | -5.4% |
Q2 2015 | $644,000 | +14.6% | 7,529 | +13.7% | 0.48% | +22.2% |
Q1 2015 | $562,000 | -2.3% | 6,619 | -1.3% | 0.40% | +0.3% |
Q4 2014 | $575,000 | +12.7% | 6,709 | 0.0% | 0.40% | +10.9% |
Q3 2014 | $510,000 | -13.6% | 6,709 | -10.5% | 0.36% | -14.0% |
Q2 2014 | $590,000 | +6.1% | 7,495 | +1.1% | 0.42% | +1.7% |
Q1 2014 | $556,000 | +49.5% | 7,415 | +53.8% | 0.41% | +52.2% |
Q4 2013 | $372,000 | -45.5% | 4,820 | -51.0% | 0.27% | +22.9% |
Q3 2013 | $682,000 | +119.3% | 9,840 | +100.0% | 0.22% | -1.4% |
Q2 2013 | $311,000 | – | 4,920 | – | 0.22% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |